Centene reaffirms 2026 earnings guidance: Centene stock gains 1.68 percent

Published on 10/05/2026 at 16:40 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue reached USD 53.58 billion in the quarter ended June 30, 2026. Centene stock costs EUR 56.92 on October 5, 2026 after EUR 55.98.

Bauhaus-Grafikposter mit großem PHARMA-Text, geometrischen Formen in Rot Blau Gelb — Cencora Inc. Pharmadistribution US15135B1017 als geometrisches Bauhaus-Poster mit großem PHARMA-Schriftzug in Rot Blau Gelb, Illustration mit AI erstellt.

Centene Corp. (ISIN US15135B1017) was trading at EUR 56.92 at Lang & Schwarz on October 5, 2026 at 4:33 p.m. CEST, up 1.68 percent from the EUR 55.98 prior close. According to the SEC filing dated September 16, 2026, management reaffirmed full-year 2026 GAAP diluted earnings per share guidance above USD 3.11 and adjusted diluted earnings per share guidance above USD 4.80.

Guidance meets a stronger quarter

The guidance followed a profitable second quarter. Centene reported USD 53.58 billion in revenue for the quarter ended June 30, 2026, up 9.90 percent year over year, while adjusted earnings per share reached USD 2.51 versus USD 1.09 consensus.

Zacks reported on September 17, 2026 that Centene's consolidated health benefits ratio improved to 89.60 percent from 93.00 percent a year earlier. The comparison points to better medical-cost control, the operating lever behind the earnings recovery.

Membership remains the counterweight

Medicaid enrollment ended the second quarter of 2026 at 12.10 million, down 5.50 percent year over year, according to Zacks. The company expects full-year 2026 Medicaid membership to decline 8.00 percent to 9.00 percent from year-end 2025, making enrollment the clearest offset to improved margins.

For 2026, Centene expects a pretax margin of 4.50 percent to 5.00 percent, while its Medicare prescription-drug business is expected to deliver a pretax margin above 3.00 percent. Those targets show why the stock reaction is increasingly tied to profitability and risk adjustment rather than membership growth alone.

Stock stays below its yearly high

Centene's primary listing is on the New York Stock Exchange. The USD 31.4 billion market capitalization and USD 31.63 to USD 69.63 52-week range provide the market context for the euro quote, with the reference price remaining below the upper end of that range.

Investing.com listed 18 analysts and an average 12-month target of USD 71.78 on October 5, 2026. The same page showed a USD 31.63 to USD 69.63 52-week range, while Cantor Fitzgerald maintained a USD 75.00 target on October 1, 2026.

Profitability now drives the debate

Centene's latest numbers present a two-sided picture: adjusted earnings per share more than doubled from the USD 1.09 consensus estimate, but Medicaid membership is moving lower. The next valuation step depends on whether medical-cost control and higher rates can offset the enrollment decline.

At Lang & Schwarz, Centene stock was trading at EUR 56.92 on October 5, 2026 at 4:33 p.m. CEST, plus 1.68 percent versus the EUR 55.98 prior close. The further course of trading is shown by the continuously updated real-time quote of Centene Corp stock.